SlideShare a Scribd company logo
1 of 36
MICRODOSING
OVERVIEW
1. INTRODUCTION
2. DEFINITION
3. GOALS OF PHASE 0
4. DESIGN OF PHASE 0 STUDY
5. MICRODOSING AND TECHNICAL ADVANCES
6. MICRODOSING AND REGULATORY ADVANCES
7. ETHICAL , STATISTICAL AND LOGICAL CONSIDERATIONS
8. ADVANTAGES
9. LIMITATIONS
10. CONCLUSION
INTRODUCTION
• Human drug development is a dynamic process that
keeps pace with the recent advances within the
pharmaceutical analytical labs, combined with a precise
understanding of the integrated pharmacokinetic,
pharmacodynamic and pharmacogenomic drug profiles.
• New drugs are a great need for many clinical conditions
but, development costs are rising and the number of
drugs receiving marketing approval has fallen.
• Further, drug development is a long, complex and
expensive activity. It typically involves a total cost of US$
500 million to 1 billion per marketed drug and is spread
over 10-15 years.
• By early 2000s, the attrition rate of clinical trials was
highest (62%) during Phase II, 45% during phase III and
significant (23%) at the time of registration.
• Suboptimal pharmacokinetics, lack of efficacy and
lack of safety are stated to be the prime reasons for
failures during drug development.
• This situation prompted the FDA to publish the document
‘CRITICAL PATH’, highlighting the problems in drug
development and encouraging novel approaches to be
incorporated into the current drug development paradigm.
• Thus, a new experimental approach was developed,
known as Phase 0 or Microdosing studies, to address
issues pertaining to drug metabolism and
pharmacokinetics.
DEFINITION
• In microdosing, extremely low, nonpharmacologically
active doses of a drug are used to define the drug's
pharmacokinetic profile in humans.
• Thus, by definition, microdosing means use of ‘less than
1/100th of the dose calculated to yield a
pharmacological effect of the test substance to a
maximum dose of < 100 micrograms’.
• However, in addition to this, the US FDA suggests a
maximum microdose of < 30 nanomoles for protein
products.
• Phase 0 trials are first-in-human clinical trials performed
under the Exploratory IND [Investigational New Drug]
Guidance of the US Food and Drug Administration.
• Unlike traditional phase I trials, these studies have no
therapeutic or diagnostic intent but instead aim to
provide only pharmacokinetic and/or pharmacodynamic
data to inform the next step in developing an agent.
• Microdosing allows not only for the selection of the drug
candidates more likely to be developed successfully, but
also for the determination of the first dose for the
subsequent Phase I clinical trial.
COMPARISON OF MICRODOSING STRATEGY AND
CONVENTIONAL PHASE 1 STUDIES
VARIABLE PHASE 1 TRIALS PHASE 0 TRIALS
Primary
endpoint
Establish the maximum
tolerated dose
Target modulation or ability to
image the target of interest
Dose
escalation
Determine safety and
toxicities
Achieve desired systemic
exposure or target modulation,
enabling dose selection for future
studies
Preclinical
biomarker
studies
Not consistently performed
before the trial
Required to have plasma drug
(PK) and preclinical biomarker
(PD) assay development and
assay qualification before the
initiation of the clinical trial
Biomarker
assays
Not performed consistently,
most phase 1 trials do not
emphasize
pharmacodynamic markers
Biomarker assays and/or imaging
studies are integrated to establish
the mechanism of action in actual
patient samples
Number of
patients
Usually >20 10–15
COMPARISON OF MICRODOSING STRATEGY AND
CONVENTIONAL PHASE 1 STUDIES
VARIABLE PHASE 1 TRIALS PHASE 0 TRIALS
Dosing Multiple Limited
Therapeutic
benefit
None expected; however,
tumour response is
evaluated to enable
continued dosing in case
evidence of clinical benefit is
found
None
Tumour
biopsies
Optional
Serial tumour biopsies required to
evaluate the effect of the drug on
its target(s)
Pharmacokin
etic/pharmac
odynamic
analysis
Samples are usually batched
and analysed at a later time
Real time
GOALS OF A PHASE 0 TRIAL
1) Provide human PK-PD relationship data for a drug prior
to Phase 1 testing.
2) Determine a dose range and sequence of
administration of a biomodulator to be used in
combination.
3) Determine whether a mechanism of action defined in
non-clinical models can be achieved in humans.
4) Refine a biomarker assay using human tissue.
5) Develop a novel imaging probe and evaluate in humans
the drug’s PK & PD effects.
6) Increase chance of success of subsequent
development of the agent.
DESIGN OF PHASE 0 STUDY
• Phase 0 trials involve a seamless, rational transition from
preclinical to clinical development.
• This requires close collaboration between laboratory, drug
development, and clinical scientists.
TYPES OF PHASE 0 STUDIES
• As supported by the US FDA Exploratory IND Studies
Guidelines.
1) Pharmacokinetics or Imaging studies:
2) Pharmacologically relevant dose studies:
3) Pharmacodynamic Endpoint studies:
 Pharmacokinetics or Imaging studies:
• To evaluate human bio-distribution and target binding
characteristics.
• Preclinical toxicology studies should demonstrate that a
dose 100 times the proposed human dose does not
induce adverse effects.
 Pharmacologically relevant dose studies:
• Evaluate human PK of two or more analogues to select a
lead agent.
• Preclinical toxicology studies must establish the no
observed adverse effect level (NOAEL) in a rodent two-
week toxicology study.
• The clinical starting dose is generally 1/50th of this dose
(not a microdose).
 Pharmacodynamic Endpoint studies:
• To evaluate whether the new molecular entity modulates
it’s intended target.
• Supporting preclinical toxicology studies are generally
short-term, modified-toxicity or safety studies in two
species.
• Dosing levels for these studies are not specified.
MICRODOSING PROCEDURE
• Once the cohort of compounds for candidate selection has
been determined, animal PK data and allometric scaling
methodology should be used to determine the possible
human therapeutic dose.
• A 14-day single-dose toxicity study should be carried out in
one animal species to meet regulatory toxicology
requirements for human microdosing.
• A microdosing CTA or exploratory IND should be submitted. If
required, 14C-labeled drug may be obtained.
• Dosing and bioanalytical methods should be standardized
and validated.
• The study should be meticulously designed to dose and
obtain bioanalytical samples for appropriately screened and
consented volunteers.
• And, finally, samples should be analyzed and the results
MICRODOSING AND TECHNICAL ADVANCES
• Ultrasensitive and specific analytical methods capable of
measuring drug and metabolite concentrations in the low
picogram to femtogram range are required.
• Most common of these are:
1) Liquid chromatography coupled with tandem mass
spectrometry (LC-MS-MS)
2) Accelerator Mass Spectrometry (AMS)
3) Positron Emission Tomography (PET)
• The choice of analytical technique is largely driven by the
expected plasma-drug concentrations and the limit of
quantification of the analytical method.
• AMS is used for determining PK data.
• PET provides PD data through real time imaging.
MEASURING TECHNIQUES USED FOR MICRODOSING
MEASURING
METHOD
LABELING OF
TESTING MATERIAL
CHARACTERISTICS
Accelerator Mass
Spectrometry (AMS)
Radioactive isotopes
with a long half life,
such as 14C
*Extremely high sensitivity
*Capable of constructive
analysis of the metabolites of
the compound *Requires large
facilities and equipment
Liquid Chromatograph
Mass Spectrometer
(LC/MS/MS)
No labeling required *Capacity for profile prediction
of the properties of a
compound
*Suitable for cassette dose test
Positron Emission
Tomography (PET)
Positron-emitting
nuclide with a short
half life, such as 11C,
13N, 18F, 15O
*Capacity to measure
distribution and concentration
of the compound in the body
*Requires large facilities and
equipment
CHOICE OF THE ANALYTICAL METHOD
• AMS Highly Sensitive (used for drugs with low
bioavailability and/or high volume of distribution)
• However, there is a growing use of LC-MS in microdosing as
it can offer certain advantages over AMS. They are:
1) In LC-MS, several candidate drugs could be tested in a
single dosing (cassette dosing).
2) LC-MS reveals structural information and resolves
compounds based on molecular weight.
3) AMS cannot distinguish parent drug from metabolites.
Hence an additional HPLC step is required to determine
the parent to metabolite ratio, which makes the process
complex.
4) AMS analysis involves a degree of sample processing
after chromatographic separation, which demands the
accurate addition of an isotopic dilutor.
MICRODOSING AND THE REGULATORY GUIDELINES
• Position paper from European Medicines Agency in 2004.
• Guidelines from the FDA in 2006.
• Guidelines from Japan in 2008.
• The ICH M3 international guideline in 2009.
• The latest ICH M3 guideline allows a microdose to be
administered to human subjects based on a single-dose
toxicity study (usually in the rat), followed by 14 days
observation, using the intended route of administration (or
via the intravenous route), plus some in vitro target
receptor data.
• The dose administered in the toxicity study should be 1000
times (EMEA) or 100 times (FDA) the human microdose.
The safety data thus obtained can be used to justify the
administration of a maximum of 100 µg of drug, either as a
MICRODOSING AND REGULATORY ADVANCES
• Accurate characterization of the kinetics of a drug over
time, after administration, is an important regulatory
requirement. This can be achieved by administration of
radio-labeled drug to the subject and following its fate in
plasma and excreta.
• Although regulatory authorities may not make
microdosing a mandatory requirement as the data can
be obtained by other methods, they may provide approval
or incentives for companies bringing certain drugs like life-
saving medications to the development and
commercialization stages more rapidly.
PHASE 0 : ETHICAL CONSIDERATIONS
Potential barriers to enrollment to be considered are (risk to
benefit ratio of the phase 0 trial ):
1) No therapeutic intent or benefit
2) Risk from research-related interventions, such as serial
tumour biopsies (in cancer studies) and computed
tomography scans
3) Fear in patients for delayed participation in or exclusion
from other clinical trials that would otherwise provide
therapeutic benefit
4) Opinion of primary physician
5) Lack of participant’s understanding of the informed
consent document
ETHICS: INFORMED CONSENT PROCESS
1) Need to clearly explain the rationale for the study
2) Difference between therapeutic trial and experimental
research needs to be explained
3) Need to clearly state that there is absolutely no
anticipated clinical benefit to the participant
4) Participants understanding is vital & measurement of
patient’s understanding is required.
PHASE 0: STATISTICAL ISSUES
• Following aspects should be considered:
1) Sample size should be generally limited to 6-15 patients.
2) Primary endpoint(s) should be defined prospectively.
3) Measure of intra-patient variability for the pre-treatment
endpoint values should be obtained, if possible.
4) The thresholds for declaring treatment effect on
efficacy(biomarker) for an individual patient, for a given
dose, based on both biological and statistical criteria
should be defined .
5) A reasonable false positive rate (10%) with high power
(90%) should be maintained across dose levels.
PHASE 0: LOGISTICAL CONSIDERATIONS
• Mechanism for selecting and prioritizing candidate agents.
• Dedicated Labs:
1) Non-clinical PD assay labs
2) Non-clinical animal models
3) Human tissue PD laboratory, capable of real-time analysis
4) PK lab capable of real-time analysis
• Research teams:
1) Clinical team with expertise in conduct of early phase trials
2) PK/PD scientists
3) Biospecimen procurement and processing staff
4) Interventional radiologists
5) Special imaging and nuclear medicine staff
6) Statisticians
• Willing patient participants
ADVANTAGES OF MICRODOSING
1) Reduces the unnecessary exposure of the participants to
the non-potential compounds, which can be rejected
earlier
2) Microdosing requires minute quantities of the drug for
safety testing. Hence, the risk of adverse events is less.
3) Lesser preclinical safety information is required. Thus,
further animal studies can be avoided with compounds
having unsuitable pharmacokinetic profiles.
4) From preliminary toxicology data of animals,
pharmacokinetic data for the initial dose selection can be
obtained in a short time of 4-6 months, whereas in Phase
I studies it takes 12-18 months.
5) Microdosing offers the potential to aid in early candidate
selection.
6) During drug development, when a large number of me-too
compounds are screened and found to have similar or
differing animal pharmacokinetics, comparative human
microdose studies can be done to establish
pharmacokinetics.
7) The cost of conducting a microdose study is phenomenally
less, as compared to a full Phase I study.
8) Microdosing could be useful in the discovery of endogenous
biomarkers, which would assist in the quantitative evaluation
of the in vivo effects of drugs.
9) Use in oncology: Phase 0 studies are designed with the
objective to establish whether an agent is modulating its
target in a tumor, and consequently whether further clinical
development is warranted at the very earliest opportunity
(before a large numbers of patients have been exposed to
potential drug-associated toxicity).
10)Drug can be assessed in vulnerable patients such as
patients with renal impairment, women in their reproductive
age, cancer patients, etc.
EMERGING USES OF MICRODOSING
1) To study drug-drug interactions and polymorphisms
(using microdose probes).
2) Measuring drug concentrations at the site of action.
3) Intravenous data: By incorporating an intravenous
microdose study into pharmacokinetic simulations, reliable
values for drug clearance in humans can be obtained.
4) Metabolic profiling: To obtain preliminary data on the
metabolism of a candidate, drug samples from microdose
studies have been metabolically profiled.
5) For early supportive data for drug delivery.
6) Used in synergy with In-silico approaches
7) Used in synergy with Pharmacogenomics and
Metabolomics
LIMITATIONS OF MICRODOSING
1) Absence of any therapeutic and/or diagnostic intent
2) Motivating volunteers to become a part of the trial is
difficult as there is no therapeutic intent
3) Very few validated biomarkers are available for
predicting the efficacy of some drugs (anti-cancer
activity).
4) Caution needs to be maintained while administering
drugs demonstrating complex/non-linear kinetics as
microdosing is still in its initial stages
5) Extends the process and increases the expenditure as
Phase 1 still needs to be carried out.
LIMITATIONS OF MICRODOSING
6) Microdose activity: There is lack of clarity on whether
the body's reaction to a particular compound is similar,
when used as microdose and in its pharmacological
dose; otherwise, it could lead to false negatives
(compound being rejected) or false positives (compound
acceptable based on microdose data but rejected
subsequently when used in pharmacological doses).
Thus, a microdose may not be able to predict the
behaviour of a clinical dose of the drug.
7) Analytical Methods: AMS (accelerator mass
spectrometry) and PET (positron emission tomography)
are radiotracer assays which have the disadvantages of
short tracer half-life and limited specificity (as assay may
include metabolites also). Also, these are costly and
scarcely available.
LIMITATIONS OF MICRODOSING
8) Compound metabolism and solubility of compound:
Many processes within the body involve the use of
specialized transporters, enzymes and binding sites,
which can be saturated such that the pharmacokinetic
profile is very different at the higher therapeutic dose than
seen with the microdose.
9) Solubility of compounds: Most compounds dissolve
rapidly at microdose levels, yielding rapid and often
extensive absorption. However, at higher therapeutic
doses, many compounds exhibit limited solubility. This
means, absorption becomes more dependent on the rate
and extent of dissolution, which cannot be predicted by
microdose. Thus, it has been suggested that the dose of
100 micrograms may be too low to achieve the full
STATUS IN INDIA
• There is no concept of Phase 0 or any other equivalent of
an Exploratory IND in Indian regulation.
• In 2007-08 the Indian Society for Clinical Research
(ISCR) proposed a change in regulation that would allow
the regulators to recognize and permit microdosing
studies in India.
• The Drugs Technical Advisory Board (DTAB)
unanimously approved the proposal together with other
far-reaching amendments in regulation.
• The proposals were, nevertheless, disregarded by the
government due to non-technical sensitivities that
surround clinical research and drug development in India.
PUBLISHED HUMAN MICRODOSE TRIALS
 CREAM Trial : Consortium for Resourcing and
Evaluating AMS Microdosing. Involved 5 drugs viz.,
Midazolam(high first pass metabolism), Diazepam,
Warfarin(long half life), Erythromycin and ZK-253
 EUMAPP : European Microdosing AMS Partnership
Programme : A study comparing in vitro, in silico,
microdose and pharmacological dose
pharmacokinetics.
 NEDO: New Energy and Industrial Technology
Development Organization (NEDO) research
THANK YOU

More Related Content

What's hot

Good Clinical Practice Guidelines (ICH GCP E6).ppt
Good Clinical Practice Guidelines (ICH GCP E6).pptGood Clinical Practice Guidelines (ICH GCP E6).ppt
Good Clinical Practice Guidelines (ICH GCP E6).pptMohamed Fazil M
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyAsma Ashraf
 
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Dinesh Gangoda
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationDr. Ramesh Bhandari
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...AbhishekJoshi312
 
Pre clinical studies
Pre clinical studiesPre clinical studies
Pre clinical studiesKirsha K S
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introductionbiinoida
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokineticsPARUL UNIVERSITY
 
toxicokinetics and saturation kinetics
toxicokinetics and saturation kineticstoxicokinetics and saturation kinetics
toxicokinetics and saturation kineticspharmacistnitish
 
Clinical trials its types and designs
Clinical trials  its types and designsClinical trials  its types and designs
Clinical trials its types and designsDevesh Aggarwal
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trailsGOURIPRIYA L S
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsDRx Tejas Kanhed
 
Phases in clinical trial
Phases in clinical trialPhases in clinical trial
Phases in clinical trialUpendra Agarwal
 
Prescription event monitoring and record linkage system
Prescription event monitoring and record linkage systemPrescription event monitoring and record linkage system
Prescription event monitoring and record linkage systemVineetha Menon
 
PHARMACOEPIDEMIOLOGY
PHARMACOEPIDEMIOLOGYPHARMACOEPIDEMIOLOGY
PHARMACOEPIDEMIOLOGYAISHASID
 

What's hot (20)

Good Clinical Practice Guidelines (ICH GCP E6).ppt
Good Clinical Practice Guidelines (ICH GCP E6).pptGood Clinical Practice Guidelines (ICH GCP E6).ppt
Good Clinical Practice Guidelines (ICH GCP E6).ppt
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...
Guidelines for Preparation of Documents, Clinical Study Report Clinical Trial...
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
 
Clinical Trial Doc.pptx
Clinical Trial Doc.pptxClinical Trial Doc.pptx
Clinical Trial Doc.pptx
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
 
Pre clinical studies
Pre clinical studiesPre clinical studies
Pre clinical studies
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introduction
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokinetics
 
Safety pharmacology
Safety pharmacologySafety pharmacology
Safety pharmacology
 
toxicokinetics and saturation kinetics
toxicokinetics and saturation kineticstoxicokinetics and saturation kinetics
toxicokinetics and saturation kinetics
 
Clinical trials its types and designs
Clinical trials  its types and designsClinical trials  its types and designs
Clinical trials its types and designs
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trails
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
 
Phases in clinical trial
Phases in clinical trialPhases in clinical trial
Phases in clinical trial
 
Prescription event monitoring and record linkage system
Prescription event monitoring and record linkage systemPrescription event monitoring and record linkage system
Prescription event monitoring and record linkage system
 
PHARMACOEPIDEMIOLOGY
PHARMACOEPIDEMIOLOGYPHARMACOEPIDEMIOLOGY
PHARMACOEPIDEMIOLOGY
 
Population pharmacokinetics
Population pharmacokineticsPopulation pharmacokinetics
Population pharmacokinetics
 

Viewers also liked

Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial SWAROOP KUMAR K
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentationdeepikashankar
 
Clinical trials flow process
Clinical trials flow processClinical trials flow process
Clinical trials flow processTamer Hifnawy
 
Introduction to clinical research
Introduction to clinical researchIntroduction to clinical research
Introduction to clinical researchPradeep H
 
Preclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsPreclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsBanhisikha Adhikari
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial rx_sonali
 
phases of clinical trial
phases of clinical trial phases of clinical trial
phases of clinical trial Rohit K.
 
Clinical trial phases 3,4,5 By Danish Ibrahim Jasnaik
Clinical trial phases 3,4,5 By Danish Ibrahim JasnaikClinical trial phases 3,4,5 By Danish Ibrahim Jasnaik
Clinical trial phases 3,4,5 By Danish Ibrahim JasnaikDanish Jasnaik
 
1 s2.0-s0016003213003104-main
1 s2.0-s0016003213003104-main1 s2.0-s0016003213003104-main
1 s2.0-s0016003213003104-mainRamalakshmi Vijay
 
History of clinical trials
History of clinical trialsHistory of clinical trials
History of clinical trialsUrmila Aswar
 
Phases of clinical trial 11.9.14
Phases of clinical trial 11.9.14Phases of clinical trial 11.9.14
Phases of clinical trial 11.9.14DR ANUP PETARE
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery processThanh Truong
 
Understanding Clinical Trials
Understanding Clinical TrialsUnderstanding Clinical Trials
Understanding Clinical TrialsBartsMSBlog
 
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERY
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERYSTRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERY
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERYTHILAKAR MANI
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesSlideTeam.net
 

Viewers also liked (20)

Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentation
 
Clinical trials flow process
Clinical trials flow processClinical trials flow process
Clinical trials flow process
 
Introduction to clinical research
Introduction to clinical researchIntroduction to clinical research
Introduction to clinical research
 
Clinical Trial Phases
Clinical Trial PhasesClinical Trial Phases
Clinical Trial Phases
 
Clinical Trials - An Introduction
Clinical Trials - An IntroductionClinical Trials - An Introduction
Clinical Trials - An Introduction
 
Preclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsPreclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugs
 
Clinical trial process
Clinical trial processClinical trial process
Clinical trial process
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial
 
phases of clinical trial
phases of clinical trial phases of clinical trial
phases of clinical trial
 
Clinical trial phases 3,4,5 By Danish Ibrahim Jasnaik
Clinical trial phases 3,4,5 By Danish Ibrahim JasnaikClinical trial phases 3,4,5 By Danish Ibrahim Jasnaik
Clinical trial phases 3,4,5 By Danish Ibrahim Jasnaik
 
1 s2.0-s0016003213003104-main
1 s2.0-s0016003213003104-main1 s2.0-s0016003213003104-main
1 s2.0-s0016003213003104-main
 
History of clinical trials
History of clinical trialsHistory of clinical trials
History of clinical trials
 
Phases of clinical trial 11.9.14
Phases of clinical trial 11.9.14Phases of clinical trial 11.9.14
Phases of clinical trial 11.9.14
 
Phases of clinical trials
Phases of clinical trialsPhases of clinical trials
Phases of clinical trials
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery process
 
Understanding Clinical Trials
Understanding Clinical TrialsUnderstanding Clinical Trials
Understanding Clinical Trials
 
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERY
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERYSTRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERY
STRUCTURE BASED DRUG DESIGN - MOLECULAR MODELLING AND DRUG DISCOVERY
 
Drug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templatesDrug discovery process style 5 powerpoint presentation templates
Drug discovery process style 5 powerpoint presentation templates
 
First in Human dose
First in Human  doseFirst in Human  dose
First in Human dose
 

Similar to Microdosing

Phase 0 and Phase 1 clinical trial
Phase 0 and Phase 1 clinical trialPhase 0 and Phase 1 clinical trial
Phase 0 and Phase 1 clinical trialDr. Yash Panchal
 
Toxicology screening and therapeutic drug monitoring (an introduction)
 Toxicology screening and therapeutic drug monitoring (an introduction)  Toxicology screening and therapeutic drug monitoring (an introduction)
Toxicology screening and therapeutic drug monitoring (an introduction) Hossamaldin Alzawawi
 
THERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYTHERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYsopi_1234
 
Toxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptxToxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptxashharnomani
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfsayedjannatfatema72
 
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...Medpace
 
Approaches of drug discovery
Approaches of drug discoveryApproaches of drug discovery
Approaches of drug discoveryGaurav Sharma
 
1 Phases of clinical trial.pptx
1 Phases of clinical trial.pptx1 Phases of clinical trial.pptx
1 Phases of clinical trial.pptxDr Abisha T
 
Special concerns in bioavaliblity and bioeqvivalence
Special concerns in bioavaliblity and bioeqvivalenceSpecial concerns in bioavaliblity and bioeqvivalence
Special concerns in bioavaliblity and bioeqvivalencePradnya Shirude
 
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trialsICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trialsAartiPal23
 
Regulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inRegulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inJAYA PRAKASH VELUCHURI
 

Similar to Microdosing (20)

Phase 0 and Phase 1 clinical trial
Phase 0 and Phase 1 clinical trialPhase 0 and Phase 1 clinical trial
Phase 0 and Phase 1 clinical trial
 
Toxicology screening and therapeutic drug monitoring (an introduction)
 Toxicology screening and therapeutic drug monitoring (an introduction)  Toxicology screening and therapeutic drug monitoring (an introduction)
Toxicology screening and therapeutic drug monitoring (an introduction)
 
THERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYTHERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEY
 
TDM Group 06.pptx
TDM Group 06.pptxTDM Group 06.pptx
TDM Group 06.pptx
 
Ppt tdm new
Ppt tdm newPpt tdm new
Ppt tdm new
 
New Drug Discovery.pptx
New Drug Discovery.pptxNew Drug Discovery.pptx
New Drug Discovery.pptx
 
Extrapolation.pptx
Extrapolation.pptxExtrapolation.pptx
Extrapolation.pptx
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Clinical trials phases 0 3
Clinical trials phases 0 3Clinical trials phases 0 3
Clinical trials phases 0 3
 
Toxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptxToxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptx
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdf
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
What’s New in Clinical Drug-drug Interaction Studies: Recommendations from Re...
 
Approaches of drug discovery
Approaches of drug discoveryApproaches of drug discovery
Approaches of drug discovery
 
Molecule to medicine
Molecule to medicineMolecule to medicine
Molecule to medicine
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
1 Phases of clinical trial.pptx
1 Phases of clinical trial.pptx1 Phases of clinical trial.pptx
1 Phases of clinical trial.pptx
 
Special concerns in bioavaliblity and bioeqvivalence
Special concerns in bioavaliblity and bioeqvivalenceSpecial concerns in bioavaliblity and bioeqvivalence
Special concerns in bioavaliblity and bioeqvivalence
 
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trialsICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
 
Regulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inRegulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics in
 

Recently uploaded

VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...narwatsonia7
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableNehru place Escorts
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...CALL GIRLS
 
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...indiancallgirl4rent
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...narwatsonia7
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...Taniya Sharma
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipurparulsinha
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiAlinaDevecerski
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...astropune
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...narwatsonia7
 
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bangalore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...Taniya Sharma
 
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 

Recently uploaded (20)

VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
 
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
(Rocky) Jaipur Call Girl - 09521753030 Escorts Service 50% Off with Cash ON D...
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
 
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bangalore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bangalore Just Call 9907093804 Top Class Call Girl Service Available
 
Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
Russian Call Girls in Delhi Tanvi ➡️ 9711199012 💋📞 Independent Escort Service...
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Faridabad Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
 
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Varanasi Just Call 9907093804 Top Class Call Girl Service Available
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
 
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Dehradun Just Call 9907093804 Top Class Call Girl Service Available
 

Microdosing

  • 2. OVERVIEW 1. INTRODUCTION 2. DEFINITION 3. GOALS OF PHASE 0 4. DESIGN OF PHASE 0 STUDY 5. MICRODOSING AND TECHNICAL ADVANCES 6. MICRODOSING AND REGULATORY ADVANCES 7. ETHICAL , STATISTICAL AND LOGICAL CONSIDERATIONS 8. ADVANTAGES 9. LIMITATIONS 10. CONCLUSION
  • 3. INTRODUCTION • Human drug development is a dynamic process that keeps pace with the recent advances within the pharmaceutical analytical labs, combined with a precise understanding of the integrated pharmacokinetic, pharmacodynamic and pharmacogenomic drug profiles. • New drugs are a great need for many clinical conditions but, development costs are rising and the number of drugs receiving marketing approval has fallen. • Further, drug development is a long, complex and expensive activity. It typically involves a total cost of US$ 500 million to 1 billion per marketed drug and is spread over 10-15 years.
  • 4. • By early 2000s, the attrition rate of clinical trials was highest (62%) during Phase II, 45% during phase III and significant (23%) at the time of registration. • Suboptimal pharmacokinetics, lack of efficacy and lack of safety are stated to be the prime reasons for failures during drug development. • This situation prompted the FDA to publish the document ‘CRITICAL PATH’, highlighting the problems in drug development and encouraging novel approaches to be incorporated into the current drug development paradigm. • Thus, a new experimental approach was developed, known as Phase 0 or Microdosing studies, to address issues pertaining to drug metabolism and pharmacokinetics.
  • 5. DEFINITION • In microdosing, extremely low, nonpharmacologically active doses of a drug are used to define the drug's pharmacokinetic profile in humans. • Thus, by definition, microdosing means use of ‘less than 1/100th of the dose calculated to yield a pharmacological effect of the test substance to a maximum dose of < 100 micrograms’. • However, in addition to this, the US FDA suggests a maximum microdose of < 30 nanomoles for protein products.
  • 6. • Phase 0 trials are first-in-human clinical trials performed under the Exploratory IND [Investigational New Drug] Guidance of the US Food and Drug Administration. • Unlike traditional phase I trials, these studies have no therapeutic or diagnostic intent but instead aim to provide only pharmacokinetic and/or pharmacodynamic data to inform the next step in developing an agent. • Microdosing allows not only for the selection of the drug candidates more likely to be developed successfully, but also for the determination of the first dose for the subsequent Phase I clinical trial.
  • 7.
  • 8. COMPARISON OF MICRODOSING STRATEGY AND CONVENTIONAL PHASE 1 STUDIES VARIABLE PHASE 1 TRIALS PHASE 0 TRIALS Primary endpoint Establish the maximum tolerated dose Target modulation or ability to image the target of interest Dose escalation Determine safety and toxicities Achieve desired systemic exposure or target modulation, enabling dose selection for future studies Preclinical biomarker studies Not consistently performed before the trial Required to have plasma drug (PK) and preclinical biomarker (PD) assay development and assay qualification before the initiation of the clinical trial Biomarker assays Not performed consistently, most phase 1 trials do not emphasize pharmacodynamic markers Biomarker assays and/or imaging studies are integrated to establish the mechanism of action in actual patient samples Number of patients Usually >20 10–15
  • 9. COMPARISON OF MICRODOSING STRATEGY AND CONVENTIONAL PHASE 1 STUDIES VARIABLE PHASE 1 TRIALS PHASE 0 TRIALS Dosing Multiple Limited Therapeutic benefit None expected; however, tumour response is evaluated to enable continued dosing in case evidence of clinical benefit is found None Tumour biopsies Optional Serial tumour biopsies required to evaluate the effect of the drug on its target(s) Pharmacokin etic/pharmac odynamic analysis Samples are usually batched and analysed at a later time Real time
  • 10. GOALS OF A PHASE 0 TRIAL 1) Provide human PK-PD relationship data for a drug prior to Phase 1 testing. 2) Determine a dose range and sequence of administration of a biomodulator to be used in combination. 3) Determine whether a mechanism of action defined in non-clinical models can be achieved in humans. 4) Refine a biomarker assay using human tissue. 5) Develop a novel imaging probe and evaluate in humans the drug’s PK & PD effects. 6) Increase chance of success of subsequent development of the agent.
  • 11. DESIGN OF PHASE 0 STUDY • Phase 0 trials involve a seamless, rational transition from preclinical to clinical development. • This requires close collaboration between laboratory, drug development, and clinical scientists.
  • 12.
  • 13. TYPES OF PHASE 0 STUDIES • As supported by the US FDA Exploratory IND Studies Guidelines. 1) Pharmacokinetics or Imaging studies: 2) Pharmacologically relevant dose studies: 3) Pharmacodynamic Endpoint studies:
  • 14.  Pharmacokinetics or Imaging studies: • To evaluate human bio-distribution and target binding characteristics. • Preclinical toxicology studies should demonstrate that a dose 100 times the proposed human dose does not induce adverse effects.
  • 15.  Pharmacologically relevant dose studies: • Evaluate human PK of two or more analogues to select a lead agent. • Preclinical toxicology studies must establish the no observed adverse effect level (NOAEL) in a rodent two- week toxicology study. • The clinical starting dose is generally 1/50th of this dose (not a microdose).
  • 16.  Pharmacodynamic Endpoint studies: • To evaluate whether the new molecular entity modulates it’s intended target. • Supporting preclinical toxicology studies are generally short-term, modified-toxicity or safety studies in two species. • Dosing levels for these studies are not specified.
  • 17. MICRODOSING PROCEDURE • Once the cohort of compounds for candidate selection has been determined, animal PK data and allometric scaling methodology should be used to determine the possible human therapeutic dose. • A 14-day single-dose toxicity study should be carried out in one animal species to meet regulatory toxicology requirements for human microdosing. • A microdosing CTA or exploratory IND should be submitted. If required, 14C-labeled drug may be obtained. • Dosing and bioanalytical methods should be standardized and validated. • The study should be meticulously designed to dose and obtain bioanalytical samples for appropriately screened and consented volunteers. • And, finally, samples should be analyzed and the results
  • 18.
  • 19. MICRODOSING AND TECHNICAL ADVANCES • Ultrasensitive and specific analytical methods capable of measuring drug and metabolite concentrations in the low picogram to femtogram range are required. • Most common of these are: 1) Liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) 2) Accelerator Mass Spectrometry (AMS) 3) Positron Emission Tomography (PET) • The choice of analytical technique is largely driven by the expected plasma-drug concentrations and the limit of quantification of the analytical method. • AMS is used for determining PK data. • PET provides PD data through real time imaging.
  • 20. MEASURING TECHNIQUES USED FOR MICRODOSING MEASURING METHOD LABELING OF TESTING MATERIAL CHARACTERISTICS Accelerator Mass Spectrometry (AMS) Radioactive isotopes with a long half life, such as 14C *Extremely high sensitivity *Capable of constructive analysis of the metabolites of the compound *Requires large facilities and equipment Liquid Chromatograph Mass Spectrometer (LC/MS/MS) No labeling required *Capacity for profile prediction of the properties of a compound *Suitable for cassette dose test Positron Emission Tomography (PET) Positron-emitting nuclide with a short half life, such as 11C, 13N, 18F, 15O *Capacity to measure distribution and concentration of the compound in the body *Requires large facilities and equipment
  • 21. CHOICE OF THE ANALYTICAL METHOD • AMS Highly Sensitive (used for drugs with low bioavailability and/or high volume of distribution) • However, there is a growing use of LC-MS in microdosing as it can offer certain advantages over AMS. They are: 1) In LC-MS, several candidate drugs could be tested in a single dosing (cassette dosing). 2) LC-MS reveals structural information and resolves compounds based on molecular weight. 3) AMS cannot distinguish parent drug from metabolites. Hence an additional HPLC step is required to determine the parent to metabolite ratio, which makes the process complex. 4) AMS analysis involves a degree of sample processing after chromatographic separation, which demands the accurate addition of an isotopic dilutor.
  • 22. MICRODOSING AND THE REGULATORY GUIDELINES • Position paper from European Medicines Agency in 2004. • Guidelines from the FDA in 2006. • Guidelines from Japan in 2008. • The ICH M3 international guideline in 2009. • The latest ICH M3 guideline allows a microdose to be administered to human subjects based on a single-dose toxicity study (usually in the rat), followed by 14 days observation, using the intended route of administration (or via the intravenous route), plus some in vitro target receptor data. • The dose administered in the toxicity study should be 1000 times (EMEA) or 100 times (FDA) the human microdose. The safety data thus obtained can be used to justify the administration of a maximum of 100 µg of drug, either as a
  • 23. MICRODOSING AND REGULATORY ADVANCES • Accurate characterization of the kinetics of a drug over time, after administration, is an important regulatory requirement. This can be achieved by administration of radio-labeled drug to the subject and following its fate in plasma and excreta. • Although regulatory authorities may not make microdosing a mandatory requirement as the data can be obtained by other methods, they may provide approval or incentives for companies bringing certain drugs like life- saving medications to the development and commercialization stages more rapidly.
  • 24. PHASE 0 : ETHICAL CONSIDERATIONS Potential barriers to enrollment to be considered are (risk to benefit ratio of the phase 0 trial ): 1) No therapeutic intent or benefit 2) Risk from research-related interventions, such as serial tumour biopsies (in cancer studies) and computed tomography scans 3) Fear in patients for delayed participation in or exclusion from other clinical trials that would otherwise provide therapeutic benefit 4) Opinion of primary physician 5) Lack of participant’s understanding of the informed consent document
  • 25. ETHICS: INFORMED CONSENT PROCESS 1) Need to clearly explain the rationale for the study 2) Difference between therapeutic trial and experimental research needs to be explained 3) Need to clearly state that there is absolutely no anticipated clinical benefit to the participant 4) Participants understanding is vital & measurement of patient’s understanding is required.
  • 26. PHASE 0: STATISTICAL ISSUES • Following aspects should be considered: 1) Sample size should be generally limited to 6-15 patients. 2) Primary endpoint(s) should be defined prospectively. 3) Measure of intra-patient variability for the pre-treatment endpoint values should be obtained, if possible. 4) The thresholds for declaring treatment effect on efficacy(biomarker) for an individual patient, for a given dose, based on both biological and statistical criteria should be defined . 5) A reasonable false positive rate (10%) with high power (90%) should be maintained across dose levels.
  • 27. PHASE 0: LOGISTICAL CONSIDERATIONS • Mechanism for selecting and prioritizing candidate agents. • Dedicated Labs: 1) Non-clinical PD assay labs 2) Non-clinical animal models 3) Human tissue PD laboratory, capable of real-time analysis 4) PK lab capable of real-time analysis • Research teams: 1) Clinical team with expertise in conduct of early phase trials 2) PK/PD scientists 3) Biospecimen procurement and processing staff 4) Interventional radiologists 5) Special imaging and nuclear medicine staff 6) Statisticians • Willing patient participants
  • 28. ADVANTAGES OF MICRODOSING 1) Reduces the unnecessary exposure of the participants to the non-potential compounds, which can be rejected earlier 2) Microdosing requires minute quantities of the drug for safety testing. Hence, the risk of adverse events is less. 3) Lesser preclinical safety information is required. Thus, further animal studies can be avoided with compounds having unsuitable pharmacokinetic profiles. 4) From preliminary toxicology data of animals, pharmacokinetic data for the initial dose selection can be obtained in a short time of 4-6 months, whereas in Phase I studies it takes 12-18 months. 5) Microdosing offers the potential to aid in early candidate selection.
  • 29. 6) During drug development, when a large number of me-too compounds are screened and found to have similar or differing animal pharmacokinetics, comparative human microdose studies can be done to establish pharmacokinetics. 7) The cost of conducting a microdose study is phenomenally less, as compared to a full Phase I study. 8) Microdosing could be useful in the discovery of endogenous biomarkers, which would assist in the quantitative evaluation of the in vivo effects of drugs. 9) Use in oncology: Phase 0 studies are designed with the objective to establish whether an agent is modulating its target in a tumor, and consequently whether further clinical development is warranted at the very earliest opportunity (before a large numbers of patients have been exposed to potential drug-associated toxicity). 10)Drug can be assessed in vulnerable patients such as patients with renal impairment, women in their reproductive age, cancer patients, etc.
  • 30. EMERGING USES OF MICRODOSING 1) To study drug-drug interactions and polymorphisms (using microdose probes). 2) Measuring drug concentrations at the site of action. 3) Intravenous data: By incorporating an intravenous microdose study into pharmacokinetic simulations, reliable values for drug clearance in humans can be obtained. 4) Metabolic profiling: To obtain preliminary data on the metabolism of a candidate, drug samples from microdose studies have been metabolically profiled. 5) For early supportive data for drug delivery. 6) Used in synergy with In-silico approaches 7) Used in synergy with Pharmacogenomics and Metabolomics
  • 31. LIMITATIONS OF MICRODOSING 1) Absence of any therapeutic and/or diagnostic intent 2) Motivating volunteers to become a part of the trial is difficult as there is no therapeutic intent 3) Very few validated biomarkers are available for predicting the efficacy of some drugs (anti-cancer activity). 4) Caution needs to be maintained while administering drugs demonstrating complex/non-linear kinetics as microdosing is still in its initial stages 5) Extends the process and increases the expenditure as Phase 1 still needs to be carried out.
  • 32. LIMITATIONS OF MICRODOSING 6) Microdose activity: There is lack of clarity on whether the body's reaction to a particular compound is similar, when used as microdose and in its pharmacological dose; otherwise, it could lead to false negatives (compound being rejected) or false positives (compound acceptable based on microdose data but rejected subsequently when used in pharmacological doses). Thus, a microdose may not be able to predict the behaviour of a clinical dose of the drug. 7) Analytical Methods: AMS (accelerator mass spectrometry) and PET (positron emission tomography) are radiotracer assays which have the disadvantages of short tracer half-life and limited specificity (as assay may include metabolites also). Also, these are costly and scarcely available.
  • 33. LIMITATIONS OF MICRODOSING 8) Compound metabolism and solubility of compound: Many processes within the body involve the use of specialized transporters, enzymes and binding sites, which can be saturated such that the pharmacokinetic profile is very different at the higher therapeutic dose than seen with the microdose. 9) Solubility of compounds: Most compounds dissolve rapidly at microdose levels, yielding rapid and often extensive absorption. However, at higher therapeutic doses, many compounds exhibit limited solubility. This means, absorption becomes more dependent on the rate and extent of dissolution, which cannot be predicted by microdose. Thus, it has been suggested that the dose of 100 micrograms may be too low to achieve the full
  • 34. STATUS IN INDIA • There is no concept of Phase 0 or any other equivalent of an Exploratory IND in Indian regulation. • In 2007-08 the Indian Society for Clinical Research (ISCR) proposed a change in regulation that would allow the regulators to recognize and permit microdosing studies in India. • The Drugs Technical Advisory Board (DTAB) unanimously approved the proposal together with other far-reaching amendments in regulation. • The proposals were, nevertheless, disregarded by the government due to non-technical sensitivities that surround clinical research and drug development in India.
  • 35. PUBLISHED HUMAN MICRODOSE TRIALS  CREAM Trial : Consortium for Resourcing and Evaluating AMS Microdosing. Involved 5 drugs viz., Midazolam(high first pass metabolism), Diazepam, Warfarin(long half life), Erythromycin and ZK-253  EUMAPP : European Microdosing AMS Partnership Programme : A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics.  NEDO: New Energy and Industrial Technology Development Organization (NEDO) research